Phenotypic drug resistance and genome sequencing based identified mutations linked to resistance in Mycobacterium tuberculosis isolated from extrapulmonary clinical specimens
Cross-sectional study reveals high drug resistance rates in Mycobacterium tuberculosis from extrapulmonary specimens in Ethiopia, suggesting genomic approaches are needed.
Key Points
To explore the extent of drug resistance and identify genetic mutations linked to Mycobacterium tuberculosis isolated from extrapulmonary specimens in Ethiopia.
Cross-sectional study conducted from August 2022 to October 2023.
189 Mycobacterium tuberculosis isolates cultured from extrapulmonary specimens were analyzed.
Phenotypic drug sensitivity testing performed using BD BACTEC MGIT 960 system and genome sequencing with Illumina NextSeq500/550.
Genomic data analyzed using MTBSeq and TBProfiler for drug resistance mutations.
16.9% prevalence of phenotypic resistance to at least one anti-TB drug.
Newly diagnosed and previously treated cases showed differing MDR-TB rates (2.4% and 21.1% respectively).
WGS detected more rifampicin resistance cases than pDST (8.75% vs 4.2%).
Identified both known and novel mutations linked to rifampicin resistance.